Accelerate Your Preclinical Research With InnoSer’s Innovative Methods.

Customizing in vitro and in vivo services for your success.

Recently At InnoSer

Get to know our preclinical drug development services at Knowledge for growth

by Joana | May 10, 2022 | Blog, Events, In Vivo, Services | 0 Comments

We are constantly looking for opportunities to exchange and develop ideas, as they are the foundation for scientific advances and innovation. In addition to our collaboration with academic and commercial partners, attending conferences such as Knowledge for Growth...

Showcasing InnoSer’s in vivo portfolio at the Dutch life sciences conference

by Casey | May 10, 2022 | Blog, Events, In Vivo, Services | 0 Comments

We are eager to join the Dutch life sciences conference - a great opportunity for high-quality networking with many start-up companies, service providers, and research organisations. This year we are happy to be showcasing our novel InnoSer Acceleration Program (ISAP)...

Novel therapeutic molecule for ADPKD presented at the ERA Congress

by Casey | May 9, 2022 | Blog, Events, Nephrology, Services | 0 Comments

We look forward to connecting and learning from other life-science companies at events such as the largest annual Nephrology Congress in Europe, the ERA Congress. Study Director Nephrology Laura Blockken will attend this year’s event, which focuses on recent...

THERAPEUTIC AREAS

We Specialize In

InnoSer’s INNOVATIVE METHODS

Combining In Vivo And In Vitro

By our state-of-the-art methods from organoids to genetically engineered mice, we provide reliability and transferability in your results.

Low success rates of drugs that are able to go from bench to the clinic continue to disappoint not only researchers and pharmaceutical companies but also patients and their families. The resulting expenses affect the costs of all drugs that reach the market.

This calls for more stringent criteria at the preclinical phase, ensuring only the drugs that are effective and safe for humans continue to the clinical phases. InnoSer excels in combining in vitro and in vivo disease modelling to offer the most reliable screening platforms.

By developing in-vitro technologies and knowledge that offer higher predictive capacity, we support the transition to a world that relies less on animal testing.

SERVICES OVERVIEW

GET IN TOUCH WITH US

Tell Us About Your Work

We always keep close contact with our customers to identify and understand their needs better. All our services can be customized for your project requirements.

START A CONVERSATION

OUR CLIENTS ABOUT US

Academic And Commercial Expertise

“We truly enjoyed working with the InnoSer team. They bring an outstanding scientific knowledge into the oncology field in combination with high flexibility. InnoSer provided us with and executed a preclinical study project tailored to our needs, and within the agreed timelines. We will definitely work with InnoSer for our future drug development needs.”

Ad van de Gorp PhD, CEO Cythura Therapeutics

“Starting a biotech company was something completely new for me. InnoSer supported me in developing the study protocol and with all additional hassle like ethical protocols, logistics, ordering study materials etc. We worked closely with the InnoSer staff and I truly appreciate their professionalism and dedication.”

Joost van Bree, CEO Saillant Therapeutics

SEE ALL TESTIMONIALS



Phone

+32 (0)11 14 07 68



Headquarters

InnoSer België NV

Agoralaan A bis
3590 Diepenbeek
Belgium



Email

info@innoserlaboratories.com



Subsidiary

InnoSer Nederland BV

Zernikedreef 9
2333 CK Leiden
The Netherlands